Abstract Number: 2175 • 2015 ACR/ARHP Annual Meeting
Comparative Study Between Coagucheck XS Versus Standard Laboratory Practice Protrombine Time for Monitoring Anticoagulant Therapy in Patients with Antiphospholipid Syndrome
Background/Purpose: Antiphospholipid Syndrome (APS) is an autoimmune disease characterized by antiphospholipid antibodies (aPL) associated with thrombosis and/or pregnancy morbidity. Although initially described in patients with systemic lupus erythematosus (SLE) it…Abstract Number: 2176 • 2015 ACR/ARHP Annual Meeting
The Ability of Recombinant Domain I of Beta-2-Glycoprotein I to Inhibit Lupus Anticoagulant Effect of IgG from Patients with APS Is Enhanced By Pegylation
Background/Purpose: Antiphospholipid Syndrome (APS) is an autoimmune rheumatic disorder in which antiphospholipid antibodies (aPL) cause clinical events including vascular thrombosis (VT) and pregnancy morbidity (PM).…Abstract Number: 2177 • 2015 ACR/ARHP Annual Meeting
Pegylated Recombinant Domain I of Beta-2-Glycoprotein I, a Potential Therapeutic Agent for Antiphospholipid Syndrome, Fully Retains Its Ability to Inhibit Binding of IgG or IgA Antibodies from Patients with APS to Beta-2-Glycoprotein I in Vitro
Background/Purpose: Antiphospholipid Syndrome (APS) is an autoimmune rheumatic disorder in which antiphospholipid antibodies (aPL) cause clinical events including vascular thrombosis (VT) and pregnancy morbidity (PM).…Abstract Number: 2178 • 2015 ACR/ARHP Annual Meeting
Oxidation of beta2-Glycoprotein I (beta2-GPI) Associates with the Presence of Antibodies to Domain I of beta2-GPI in Patients with the Antiphospholipid Syndrome but Is Not Affected By the Antibodies in Vivo in a Rat Model
Background/Purpose: β2GPI represents the major antigenic target for antiphospholipid antibodies (aPL), the hallmark of antiphospholipid syndrome (APS). β2GPI contains five homologous domains, with domain I…Abstract Number: 2179 • 2015 ACR/ARHP Annual Meeting
Signaling By Mammalian Target of Rapamycin (mTORC) Highlight Pathological IgG and IgA in SLE Patients with Secondary APS
Background/Purpose: The spectrum of the vascular pathology affecting SLE patients with secondary antiphospholipid syndrome includes vasculopathy with endothelial cell hyperplasia as in APS nephropathy. Previous…Abstract Number: 2180 • 2015 ACR/ARHP Annual Meeting
Primary Antiphospholipid Syndrome Patients Display Increased Levels of Cell-Bound C4d in Comparison to SLE and Healthy Donors
Background/Purpose: Systemic Lupus Erythematosus (SLE) patients display high levels of the cell-bound complement activation factor C4d deposits on erythrocytes, B lymphocytes and platelets. In particular,…Abstract Number: 2181 • 2015 ACR/ARHP Annual Meeting
Antiphospholipid Antibody-Mediated Increase of Tissue Factor in Arterial Wall Is Associated with Increased Thrombus Size in a Mouse Model
Background/Purpose: Antiphospholipid syndrome (APS) is a multisystemic autoimmune disease characterized by recurrent thrombotic and adverse obstetric events in the presence of antiphospholipid antibodies (aPL). Compelling…Abstract Number: 2182 • 2015 ACR/ARHP Annual Meeting
Increased Risk of Livedo Reticularis Associated with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Background/Purpose : Livedo reticularis (LR) is present in patients with systemic lupus erythematosus (SLE), and the role of antiphospholipid antibodies (aPL) is controversial. Therefore our…Abstract Number: 2183 • 2015 ACR/ARHP Annual Meeting
Clinical and Epidemiological Correlates of the Adjusted Global Anti-Phospholipid Syndrome Score in a Large Cohort of Chinese APS Patients
Background/Purpose: It is well known that anti-phospholipid antibodies (aPL) are associated with an increased risk of arterial and venous thrombosis and pregnancy loss/morbidity. However, anticoagulation…Abstract Number: 2184 • 2015 ACR/ARHP Annual Meeting
Non-Criteria Clinical Manifestations in Antiphospholipid Syndrome: Clinical Behavior and Association with Damage Accrual
Background/Purpose: The relevance of non-criteria clinical manifestations of antiphospholipid syndrome (APS) has been less studied than its thrombotic and obstetric features. The aim of this…Abstract Number: 2185 • 2015 ACR/ARHP Annual Meeting
Small but Clinically Insignificant Decreases in Antiphospholipid Antibody Titers Occur in aPL-Positive Patients during Pregnancy
Background/Purpose: The presence of aPL has been associated with pregnancy complications, but the evolution of aPL titers during pregnancy in aPL-positive patients and the utility…Abstract Number: 2186 • 2015 ACR/ARHP Annual Meeting
The Role of Hydroxychloroquine Treatment on Pregnancy Outcome in Women with Antiphospholipid Antibodies
Background/Purpose: With good management, around 70% of pregnant women with Antiphospholipid Syndrome (APS) will deliver a viable live infant.However, current management does not prevent all…Abstract Number: 2187 • 2015 ACR/ARHP Annual Meeting
Anti-Phosholipid Antibodies and Female Infertility: A Systematic Revision of Literature
Background/Purpose: Infertility is a common condition, affecting 8-12% of couples in childbearing age. Even though the association of aPL with infertility is highly debated, infertile…Abstract Number: 2188 • 2015 ACR/ARHP Annual Meeting
Antiphospholipid Antibodies and the Risk of Damage Accrual in Systemic Lupus Erythematosus
Background/Purpose: A limited number of studies evaluated the impact of antiphospholipid antibodies (aPL) on organ damage in Systemic Lupus Erythematosus (SLE) with contrasting conclusions. The…Abstract Number: 2189 • 2015 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository (“Registry”) Prospective Follow-up Analysis: One-Year First and Recurrent Thrombosis Risk
Background/Purpose: APS ACTION “Registry” was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic…
ACR Meeting Abstracts